Robert Arthur Craigie, Ph.D.
Molecular Virology Section, Laboratory of Molecular Biology
Building 5, Room 301
5 Memorial Dr
Bethesda, MD 20814
+1 301 496 4081
Our research focuses on mechanistic aspects of retroviral DNA integration. After entering the host cell, a DNA copy of the viral genome is made by reverse transcription. Integration of this viral DNA into a chromosome of the host cell is an essential step in the retroviral replication cycle.
The key player in the retroviral DNA (deoxyribonucleic acid) integration process is the virally encoded integrase protein. Integrase processes the ends of the viral DNA and covalently inserts these processed ends into host DNA. These reactions are catalyzed within a nucleoprotein complex between integrase and viral DNA ends called the intasome. We study the molecular mechanism of these reactions using biochemical, biophysical, and structural techniques. Currently approved drugs that target HIV-1 DNA integration target the intasome. Recent efforts have focused on biochemical and structural studies of HIV-1 intasomes. High-resolution structures of HIV-1 intasomes are needed to understand the detailed molecular mechanism of how these drugs act and how the virus can escape by developing resistance. We have devised methods to make HIV-1 intasomes amenable to structural studies by high-resolution cryo-electron microscopy. We now have high-resolution structures of HIV-1 intasomes in complex with all the currently FDA approved integrase inhibitors and are now focused on studying how mutation in HIV-1 integrase can confer drug resistance.
Cellular proteins play important accessory roles in the integration process. A focus of our research on cellular factors has been the mechanism that prevents integrase using the viral DNA as a target for integration. Such autointegration would result in destruction of the viral DNA. We have identified a cellular protein, which we called barrier-to-autointegration factor (BAF), that prevents integration of the viral DNA into itself. BAF is a DNA bridging protein that bridges together segments of double-stranded DNA. At high DNA concentration, this would result in aggregation. However, at low DNA concentration, such as the few copies of viral DNA in the cytoplasm of an infected cell, the DNA bridging property of BAF results in intracellular compaction. Our model is that compaction of the viral DNA by BAF makes it inaccessible as a target for integration.
Applying our Research
This research will help the public with understanding the mechanism of action of HIV-1 integrase inhibitors and how the virus is able to develop resistance and guide the design of improved inhibitors.
- Ph.D., London, 1982
- B.S., London, 1978
Li M, Chen X, Wang H, Jurado KA, Engelman AN, Craigie R. A Peptide Derived from Lens Epithelium-Derived Growth Factor Stimulates HIV-1 DNA Integration and Facilitates Intasome Structural Studies. J Mol Biol. 2020;432(7):2055-2066.
Passos DO, Li M, Jóźwik IK, Zhao XZ, Santos-Martins D, Yang R, Smith SJ, Jeon Y, Forli S, Hughes SH, Burke TR Jr, Craigie R, Lyumkis D. Structural basis for strand-transfer inhibitor binding to HIV intasomes. Science. 2020;367(6479):810-814.
Passos DO, Li M, Yang R, Rebensburg SV, Ghirlando R, Jeon Y, Shkriabai N, Kvaratskhelia M, Craigie R, Lyumkis D. Cryo-EM structures and atomic model of the HIV-1 strand transfer complex intasome. Science. 2017;355(6320):89-92.
Li M, Jurado KA, Lin S, Engelman A, Craigie R. Engineered hyperactive integrase for concerted HIV-1 DNA integration. PLoS One. 2014;9(8):e105078.
Craigie R. The road to HIV-1 integrase inhibitors: the case for supporting basic research. Future Virol. 2014;9(10):899-903.
Related Scientific Focus Areas
Molecular Biology and Biochemistry
This page was last updated on June 3rd, 2021